CPWM
RXRX icon

Cypress Point Wealth Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Cypress Point Wealth Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-14,219
Closed -$94.8K – 44
2023
Q1 		$94.8K Hold
14,219
– – 0.13% 37
2022
Q4 		$110K Buy
14,219
+4,063
+40% +$39.8K 0.17% 35
2022
Q3 		$108K Buy
+10,156
New +$103K 0.2% 22

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $78.6M AUM 55.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Laurion Capital Management
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Cypress Point Wealth Management's RXRX Position: Q2 2023 in Review

Cypress Point Wealth Management sold out of Recursion Pharmaceuticals (RXRX) in Q2 2023, closing a stake of 14,219 shares — an estimated $94.8K sold.

Cypress Point Wealth Management first reported a position in RXRX in Q3 2022 and held it in 3 quarters. The position peaked at $110K in Q4 2022. 157 funds tracked by Wall St. Rank hold RXRX as of Q2 2023.

  • Cypress Point Wealth Management reported no remaining Recursion Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Cypress Point Wealth Management sold 14,219 Recursion Pharmaceuticals shares in Q2 2023, an estimated $94.8K.
  • Cypress Point Wealth Management first reported a position in Recursion Pharmaceuticals in Q3 2022 and held it in 3 quarters.
  • Cypress Point Wealth Management's Recursion Pharmaceuticals position peaked at $110K in Q4 2022.
  • 157 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2023.

Based on Cypress Point Wealth Management's 13F filing for Q2 2023, filed 20 Jul 2023.